Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Diabetologists (US)

Articles with lock require a subscription to GLG News | Request a free trial
November 24, 2008
perspective on diabetes treatments
Analysis of: Are Costly Diabetes Pills Doing Any Good? | www.pharmalot.com
Author: GLG Expert Contributor
1. Yes, more expensive glucose-lowering drugs are being more widely used. 2. No, I do not think that medical evidence suggests that this is incorrect.
August 6, 2008
More questions than answers:
Analysis of: Drugs to Build Bones May Weaken Them | www.nytimes.com
Author: GLG Expert Contributor
 Should bisphosphonates be stopped in patients who have been taking them for many years?  Should they be used at all?
July 7, 2008
Cost implications of July 1-2 FDA panel
Analysis of: Drug Makers Say FDA Safety Focus Is Slowing New-Medicine Pipeline | online.wsj.com
Author: GLG Expert Contributor
Therapeutic effects of drugs are seen essentially in all treated patients.  Adverse outcomes are infrequent.  The July 1-2 FDA diabetes panel recommendation that sturdy systems for determining outcome should be required for all new diabetes treatments may lead to a >100-fold increase in...
June 23, 2008
Doctors don't profit from EHRs
Analysis of: Most Doctors Aren’t Using Electronic Health Records | www.nytimes.com
Author: GLG Expert Contributor
Third party payers benefit the most from EHRs because it makes charts easier to audit   The cost of implementing an EHR is excessive for a small practice of 2-5 physicians.
May 14, 2008
Decreased DEXA reimbursement implications
Analysis of: DXA Reimbursement Reductions: Implications for Quality Osteoporosis Care, Marjorie Luckey, MD and Roberta Biegel (Washington, DC: National Osteoporosis Foundation, Winter 2005) | osteoporosisblogger.com
Author: GLG Expert Contributor
key implications: Less reimbursements for DEXA may lead to less testing, as cost of leasing equipment will be greater then revenue derived form procedures However, Less revenue/procedure could lead to greater utilization of equipment to cover costs involved and result in earlier testing of women...
April 7, 2008
Taranabant Drections: To Success or to Failure?
Analysis of: Taranabant looks promising | www.taranabant-health.com
Author: GLG Expert Contributor
The article shows that Taranabant is promising anti-obesity drug that may have better luck with the FDA than Rimonabant. Although the trial results are excellent, the company removed higher doses from future trials! What we should learn from Rimonabant failure and Exenatide success?
April 7, 2008
Taranabant directions: To gain or to Failure
Analysis of: Phase III Data Showed Taranabant, Merck's Investigational Medicine to Treat Obesity, Led to Statistically Significant Weight Loss | pharmalive.com
Author: GLG Expert Contributor
The market is hungry for a weight loss drug with diabetes benefit. Currently, the FAD has phobia of the SEs with new drugs in this category Failure of Rimonabant was due to wrong direction of Sanofi Aventis in their approach to the FDA Taranabant may have better luck, especially if Merck take...
Joseph BassMarch 28, 2008
Another Glinide: Where's the Beef?
Analysis of: Elixir Announces Completion of Enrollment in Pivotal Phase III Clinical Trial for New Diabetes Drug | www.pipelinereview.com
Author: Joseph Bass, Division Head of Endocrinology and Metabolism, Evanston Northwestern Healthcare
Elixir has turned to a strategy devoid of innovation by selecting a combination glinide (metiglinide) plus glucophage for treatment of type 2 diabetes.  With the new availability of DPP4 inhibitors (sitagliptin/alogliptin) and incretin agonists (eg byetta), what is the prospect of another K channel...
Joseph BassFebruary 8, 2008
Warning on A1C Targets and Diabetes Death in ACCORD Trial
Analysis of: Hault of ACCORD Study Intensive Treatment Arm | www.nhlbi.nih.gov
Author: Joseph Bass, Division Head of Endocrinology and Metabolism, Evanston Northwestern Healthcare
Increased death from intensive A1C lowering in diabetic subjects raises new concerns about diabetes therapy, insulin use in combination with oral agents, and clinical biomarkers of disease complications.
Joseph BassFebruary 5, 2008
Predicting Winners in Oral Diabetes Competition: Galvus, Alogliptin & Januvia
Analysis of: Galvus(R), A New Treatment For Patients With Type 2 Diabetes, Receives European Approval For Label Update Paving The Way For EU Launches | www.pipelinereview.com
Author: Joseph Bass, Division Head of Endocrinology and Metabolism, Evanston Northwestern Healthcare
Oral therapies improve complianceEU approval of Galvus does not erase US doubts

Page : 1 2 3 4 5 6 7 8 Next1 to 10 of 73

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-02T17:45:17.163